華森製藥(002907.SZ):獲得平消片的藥品再註冊批準通知書
格隆匯5月28日丨華森製藥(002907.SZ)公佈,公司於近日收到重慶市藥品監督管理局覈準簽發的關於公司藥品平消片的《藥品再註冊批準通知書》。
平消片爲公司生產的國家基藥、醫保甲類抗腫瘤中成藥,具有扶正祛邪、解毒止痛、活血化瘀、散結消腫之功效,配合放、化療協同治療多種惡性腫瘤,在延長患者生存期、改善生活質量、緩解症狀、提高機體免疫功能和降低放、化療毒副反應等方面效果顯著,具有減毒增效的作用。同時對癌前病變如乳腺增生、甲狀腺結節、子宮肌瘤等療效突出,可軟化包塊、縮小囊腫、減輕症狀。
平消片被列入《腫瘤中醫診療指南》《中醫外科常見病診療指南》《中成藥臨牀應用指南·消化疾病分冊》《中成藥臨牀應用指南·呼吸系統疾病分冊》《臨牀路徑治療藥物釋義腫瘤疾病分冊》《中醫臨牀診療指南釋義》《國家基本藥物臨牀應用指南(中成藥)》等多項臨牀指南或專家共識。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.